American College of Cardiology Supports FDA Efforts to End Access to Menthol Cigarettes, Flavored Cigars

American College of Cardiology President Dipti Itchhaporia, MD, FACC, made the following statement on the U.S. Food and Drug Administration’s (FDA) commitment to ban menthol cigarettes and flavored cigarettes.

“Tobacco use is the leading cause of preventable death in the United States and a significant, modifiable risk factor for heart disease, which is the No. 1 cause of death in the United States. This should give us ample reason to take every action available to reduce tobacco’s impact on our society and public health. The American College of Cardiology is heartened to see the FDA’s recent commitment to advance bans on menthol flavored cigarettes and all flavored cigars. The ACC has joined with stakeholders in recent years to call for this change as an imperative to public health.

It is already known that flavored products are often targeted at and used by our youth population. It is why flavored e-cigarettes have already been banned and why we have raised the age to use tobacco products to 21.

We all understand the stakes of tobacco products and addiction on our communities’ health. Menthol cigarettes are well-known to increase youth initiation to smoking; they also increase addiction to nicotine and reduce success in smoking cessation.

We also know that menthol cigarettes have an incredibly high toll in the disease and death in the Black community, worsening existing and unacceptable health disparities. The ACC, the public health community, the FDA and Congress must work together on this vital issue with clear public health benefits of reducing tobacco-related death and disease.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”